Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis

Lawrence Mbuagbaw; Lorenzo Guglielmetti; Catherine Hewison; Nyasha Bakare; Mathieu Bastard; Eric Caumes; Mathilde Fréchet-Jachym; Jérôme Robert; Nicolas Veziris; Naira Khachatryan; Tinatin Kotrikadze; Armen Hayrapetyan; Zaza Avaliani; Holger J. Schünemann; Christian Lienhardt

doi:10.3201/eid2505.181823

Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis

Lawrence Mbuagbaw
, Lorenzo Guglielmetti
, Catherine Hewison
, Nyasha Bakare
, Mathieu Bastard
, Eric Caumes
, Mathilde Fréchet-Jachym
, Jérôme Robert
, Nicolas Veziris
, Naira Khachatryan
, Tinatin Kotrikadze
, Armen Hayrapetyan
, Zaza Avaliani
, Holger J. Schünemann
, Christian Lienhardt

Department of Epidemiology and Environmental Health

University at Buffalo

McMaster University
Centre for the Development of Best Practices in Health
INSERM
Centre Hospitalier de Bligny
Sorbonne Université
Medecins Sans Frontieres
Johnson & Johnson
Epicentre
Hôpitaux Universitaires de l’Est Parisien
National Tuberculosis Control Centre
National Center for Tuberculosis and Lung Diseases
World Health Organization
Université de Montpellier

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%–81.9%), and the treatment success rate was 65.8% (95% CI 59.9%–71.3%). Death rate was 11.7% (95% CI 7.0%–19.1%). Up to 91.1% (95% CI 82.2%–95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%–23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.

Original language	English
Pages (from-to)	936-943
Number of pages	8
Journal	Emerging infectious diseases
Volume	25
Issue number	5
DOIs	https://doi.org/10.3201/eid2505.181823
State	Published - May 2019

Access to Document

10.3201/eid2505.181823

Cite this

Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., Fréchet-Jachym, M., Robert, J., Veziris, N., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Schünemann, H. J., & Lienhardt, C. (2019). Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerging infectious diseases, 25(5), 936-943. https://doi.org/10.3201/eid2505.181823

@article{4738a01c64574a809a2bc4b67372f80f,

title = "Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis",

abstract = "Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78\% (95\% CI 73.5\%–81.9\%), and the treatment success rate was 65.8\% (95\% CI 59.9\%–71.3\%). Death rate was 11.7\% (95\% CI 7.0\%–19.1\%). Up to 91.1\% (95\% CI 82.2\%–95.8\%) of the patients experienced >1 adverse event, and 11.2\% (95\% CI 5.0\%–23.2\%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.",

author = "Lawrence Mbuagbaw and Lorenzo Guglielmetti and Catherine Hewison and Nyasha Bakare and Mathieu Bastard and Eric Caumes and Mathilde Fr{\'e}chet-Jachym and J{\'e}r{\^o}me Robert and Nicolas Veziris and Naira Khachatryan and Tinatin Kotrikadze and Armen Hayrapetyan and Zaza Avaliani and Sch{\"u}nemann, \{Holger J.\} and Christian Lienhardt",

year = "2019",

month = may,

doi = "10.3201/eid2505.181823",

language = "English",

volume = "25",

pages = "936--943",

journal = "Emerging infectious diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "5",

}

Mbuagbaw, L, Guglielmetti, L, Hewison, C, Bakare, N, Bastard, M, Caumes, E, Fréchet-Jachym, M, Robert, J, Veziris, N, Khachatryan, N, Kotrikadze, T, Hayrapetyan, A, Avaliani, Z, Schünemann, HJ & Lienhardt, C 2019, 'Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis', Emerging infectious diseases, vol. 25, no. 5, pp. 936-943. https://doi.org/10.3201/eid2505.181823

TY - JOUR

T1 - Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis

AU - Mbuagbaw, Lawrence

AU - Guglielmetti, Lorenzo

AU - Hewison, Catherine

AU - Bakare, Nyasha

AU - Bastard, Mathieu

AU - Caumes, Eric

AU - Fréchet-Jachym, Mathilde

AU - Robert, Jérôme

AU - Veziris, Nicolas

AU - Khachatryan, Naira

AU - Kotrikadze, Tinatin

AU - Hayrapetyan, Armen

AU - Avaliani, Zaza

AU - Schünemann, Holger J.

AU - Lienhardt, Christian

PY - 2019/5

Y1 - 2019/5

N2 - Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%–81.9%), and the treatment success rate was 65.8% (95% CI 59.9%–71.3%). Death rate was 11.7% (95% CI 7.0%–19.1%). Up to 91.1% (95% CI 82.2%–95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%–23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.

AB - Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%–81.9%), and the treatment success rate was 65.8% (95% CI 59.9%–71.3%). Death rate was 11.7% (95% CI 7.0%–19.1%). Up to 91.1% (95% CI 82.2%–95.8%) of the patients experienced >1 adverse event, and 11.2% (95% CI 5.0%–23.2%) experienced a serious adverse event. Lung cavitations were consistently associated with unfavorable outcomes. The use of bedaquiline in MDR and XDR TB treatment regimens appears to be effective and safe across different settings, although the certainty of evidence was assessed as very low.

UR - https://www.scopus.com/pages/publications/85065030738

U2 - 10.3201/eid2505.181823

DO - 10.3201/eid2505.181823

M3 - Article

C2 - 31002070

SN - 1080-6040

VL - 25

SP - 936

EP - 943

JO - Emerging infectious diseases

JF - Emerging infectious diseases

IS - 5

ER -

Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this